In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioLuminate, Inc.

http://www.bioluminate.com

Latest From BioLuminate, Inc.

The Evolving World Of Breast Cancer Management

The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.

Medical Device Surgical Procedures

NovaScan LLC

The rates of reoperation after breast conservation therapy vary between 25 and 49%, due to the presence of tumor cells remaining in the surrounding tissue after the tumor is removed. NovaScan hopes to reduce the need for these reoperations. Its FastPath residual cancer probe is designed to identify normal, benign and malignant tissue types remaining inside the surgical cavity and in excised tissue in real time during surgery.

Medical Device

Improving Breast Cancer Outcomes Through Early Detection

This year, more than 192,000 women will be newly diagnosed with breast cancer, according to "US Markets for Breast Cancer Detection and Diagnostic Technologies," a report recently issued by Medtech Insight. Breast cancer represents a medical market growing through demographics, but also driven by advances in technology. The US market for breast cancer screening and diagnosis, which totaled more than $2.1 billion in 2008, is expected to grow at a healthy annual clip of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, including impending health care reform and cost/reimbursement issues.

BioLuminate Inc.

Every week just under 19,000 breast biopsies are performed in the US to find only 2,800 cancers. While tissue biopsies will always be necessary to determine the degree, invasiveness and stage of masses that are cancerous, the founder of BioLuminate thought there ought to be a less invasive way to initially rule out cancer to prevent large numbers of biopsies on benign tissue. He believes he's found it in smart probe technology licensed from NASA.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • Other Names / Subsidiaries
    • BioLuminate Inc.
UsernamePublicRestriction

Register